Veradermics (NYSE:MANE) Director Sells 100,000 Shares of Stock

Veradermics, Incorporated (NYSE:MANE) Director John Childs sold 100,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total value of $10,712,000.00. Following the completion of the transaction, the director directly owned 194,117 shares in the company, valued at approximately $20,793,813.04. This represents a 34.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Veradermics Price Performance

Shares of Veradermics stock traded up $2.18 during trading hours on Friday, hitting $113.18. 523,366 shares of the company’s stock traded hands, compared to its average volume of 601,161. Veradermics, Incorporated has a 12-month low of $32.00 and a 12-month high of $131.24. The stock has a market capitalization of $4.73 billion and a PE ratio of -85.74. The stock’s fifty day moving average is $109.45.

Veradermics (NYSE:MANE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.58). Sell-side analysts anticipate that Veradermics, Incorporated will post -2.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MANE has been the subject of a number of research reports. Wall Street Zen raised shares of Veradermics from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Citigroup lifted their price target on shares of Veradermics from $135.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Jefferies Financial Group upped their price objective on Veradermics from $138.00 to $182.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. UBS Group set a $170.00 price objective on Veradermics in a report on Wednesday, July 15th. Finally, B. Riley Financial initiated coverage on Veradermics in a research report on Wednesday, July 15th. They issued a “buy” rating and a $170.00 target price for the company. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $153.00.

About Veradermics

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.